What are the differences between ocrelizumab (Ocrevus) and rituximab (Rituxan) for a patient with highly active relapsing‑remitting multiple sclerosis?

Ocrelizumab vs Rituximab for Highly Active Relapsing-Remitting Multiple Sclerosis

For highly active relapsing-remitting MS, ocrelizumab (Ocrevus) is the preferred choice over rituximab based on FDA approval, superior relapse suppression in real-world studies, and established safety profile, though rituximab remains a reasonable off-label alternative when cost or access is a barrier.

Key Differences

Regulatory Status and Approval

• Ocrelizumab: FDA-approved specifically for relapsing forms of MS and primary progressive MS 1
• Rituximab: Used off-label for MS; approved only for other conditions (rheumatoid arthritis, lymphomas)

Molecular Structure

• Ocrelizumab: Humanized monoclonal anti-CD20 antibody
• Rituximab: Chimeric monoclonal anti-CD20 antibody (more immunogenic due to mouse protein components)

Clinical Effectiveness: The Evidence Diverges

Most Recent Head-to-Head Trial (2026)

The OVERLORD-MS trial 2 demonstrated noninferiority of rituximab to ocrelizumab in newly diagnosed patients:

• No new/enlarging T2 lesions (months 6-24): 92.2% rituximab vs 94.8% ocrelizumab
• Risk difference: -2.6% (95% CI: -9.4 to 4.3), meeting noninferiority criteria
• Similar relapse rates and disability outcomes

However, this conflicts with earlier real-world evidence showing rituximab inferiority.

Real-World Registry Studies Show Different Results

2023 MSBase/Danish Registry Study 3 (1,613 patients):

• Rituximab had 1.8× higher relapse rate than ocrelizumab (rate ratio 1.8; 95% CI 1.4-2.4)
• ARR: 0.20 (rituximab) vs 0.09 (ocrelizumab), p<0.001
• Failed to demonstrate noninferiority
• 2.1× higher cumulative hazard of relapses with rituximab

2026 British Columbia Study 4:

• Elevated ARR ratio for rituximab: 1.76 (95% CI 0.70-4.59)
• Elevated relapse hazard: HR 2.17 (95% CI 0.91-5.1)
• Study underpowered due to very low overall relapse rates

2026 Finnish Study 5 (112 matched patients):

• Comparable effectiveness: ARR 0.03 in both groups
• Similar relapse-free survival (HR 0.95; 95% CI 0.21-4.33)
• No difference in MRI activity or disability progression

Reconciling the Conflicting Evidence

The discrepancy likely reflects:

1. Dosing variability: Real-world rituximab dosing is heterogeneous; RCTs use standardized protocols
2. Patient selection: Registry studies include broader populations with variable disease severity
3. Follow-up duration: Longer real-world follow-up may capture more relapses
4. Statistical power: Very low relapse rates in both groups make definitive comparisons difficult

Safety Profile

Infection Risk

2026 Swedish Nationwide Cohort 6 (16,872 treatment episodes):

• Similar infection rates between rituximab and ocrelizumab
• Both associated with higher infection risk than other DMTs
• No significant difference in serious infections between the two anti-CD20 agents

Ocrelizumab-Specific Safety Concerns (FDA Label) 1:

• Increased malignancy risk: Breast cancer in 6/781 females (0.77%) vs 0/668 controls
• Progressive multifocal leukoencephalopathy (PML): Reported in postmarketing surveillance
• Immunoglobulin reduction: IgG depletion associated with increased serious infections over 7 years
• Immune-mediated colitis: Severe cases requiring hospitalization reported postmarketing
• Infusion reactions: Common, require premedication

Practical Safety Differences

• Rituximab: More infusion reactions due to chimeric structure (higher immunogenicity)
• Ocrelizumab: More comprehensive long-term safety data from pivotal trials
• Both: Require immunoglobulin monitoring, infection surveillance, and PML vigilance

Clinical Decision Algorithm

Choose Ocrelizumab When:

1. Newly diagnosed highly active RRMS requiring maximum relapse suppression
2. Insurance covers FDA-approved therapy
3. Patient has no contraindications to humanized antibodies
4. Breast cancer screening is feasible (females)

Choose Rituximab When:

1. Cost is prohibitive for ocrelizumab (rituximab is significantly cheaper)
2. Access to ocrelizumab is limited
3. Patient has already responded well to rituximab
4. Switching from ocrelizumab due to insurance/access issues (no disease reactivation observed 5)

Both Are Appropriate High-Efficacy Options Per Guidelines

The 2025 ECTRIMS/EBMT guidelines 7 list both ocrelizumab and rituximab among high-efficacy DMTs for highly active MS, recommending:

• Early use in highly active disease
• Consider after failure of single high-efficacy DMT
• Use in patients with frequent relapses, incomplete recovery, high MRI lesion burden

Monitoring Requirements (Both Agents)

Baseline:

• Quantitative immunoglobulins (IgG, IgM, IgA)
• Hepatitis B/C screening
• Complete blood count with differential
• Pregnancy test (females of childbearing potential)

During Treatment:

• Immunoglobulin levels every 6-12 months
• MRI surveillance for PML (especially if new neurological symptoms)
• Infection monitoring
• Breast cancer screening (ocrelizumab) 1
• B-cell counts if considering live vaccines

Common Pitfalls to Avoid

1. Assuming equivalence: While the 2026 RCT showed noninferiority 2, real-world data suggest ocrelizumab may provide superior relapse control in routine practice 3

2. Ignoring dosing protocols: Rituximab effectiveness depends on adequate dosing (typically 500-1000mg every 6 months); suboptimal dosing may explain inferior real-world outcomes

3. Overlooking immunoglobulin depletion: Both agents cause progressive IgG decline; monitor closely and consider discontinuation if recurrent serious infections occur 1

4. Delaying live vaccines: Counsel patients about vaccination needs before starting therapy; B-cell depletion persists 6+ months after last dose

5. Missing PML warning signs: Maintain high index of suspicion for subacute neurological changes; MRI may show findings before symptoms 1